"Data accessibility","Study","Disease","Sex","Population included","Sample type","Investigation type","Study design","Households","Variables","Approved requests","Participants","Percent approved","Total requests","Participant repeated measures","Samples","Country","Years","Additional data","WHO indicator subdomain","Project name","Eda study ID","Contact","Contact institution","Release # and date","Build Number Introduced","Data Set Name","dataset_id","Short Attribution","Summary","Type"
"Public","WASH Benefits Kenya Cluster Randomized Trial","Diarrheal disease","Female, Male","Neonate, Infant, Child","No samples","Experimental","Randomized controlled/clinical trial","8,246","72","N/A","13,574","N/A","N/A","40,722","N/A","Kenya","2012, 2013, 2014, 2015","N/A","Reproductive, maternal, newborn, child and adolescent health, Communicable disease","WASH Benefits","WASHBKEN0-1","Andrew Mertens","University of California, Berkeley, CA, USA","ClinEpiDB rel. 21, 2022-MAR-03","16","ISASimple_Gates_WASHb_Kenya_rct_RSRC","DS_010e5612b8","Andrew Mertens","WASH Benefits Kenya was a cluster-randomized trial that assessed improvements in water quality, sanitation, handwashing (WASH interventions) and child nutrition on the primary outcomes of child growth and diarrhea. Geographically matched clusters (groups of household compounds) were randomized to one of six intervention arms (1. water quality, 2. sanitation, 3. handwashing, 4. nutrition, 5. combined water quality + sanitation + handwashing, and 6. combined water quality + sanitation + handwashing + nutrition) or two control arms (1. active, and 2. passive). Newborns from rural households in Kenya were enrolled and outcomes were measured at 12 and 24 months after intervention delivery.","N/A"
"Public","India ICEMR Cohort","Malaria","Female, Male","Child, Adult","Blood sample","Observational","Cohort","110","166","N/A","397","N/A","N/A","1,249","1,249","India","2013, 2014, 2015","N/A","Communicable disease","ICEMR","INDIA0001-1","Jane Carlton","New York University, New York City, NY, USA","ClinEpiDB rel. 6, 2019-MAR-07","6","ISASimple_ICEMR_India_longitudinal_RSRC","DS_05ea525fd3","Jane Carlton","A longitudinal cohort study of malaria in different transmission settings was conducted at two sites in India. Participants of all ages were randomly identified from household censuses that were conducted and visited roughly every 3 months.","N/A"
"Prerelease","VIDA Case Control","Diarrheal disease","Female, Male","Neonate, Infant, Child","Stool sample","Observational","Case-control","11,053","514","N/A","11,053","N/A","N/A","23,553","11,053","Kenya, Mali, The Gambia","2015, 2016, 2017, 2018","N/A","Reproductive, maternal, newborn, child and adolescent health, Communicable disease","VIDA","VIDACC-1","Gates Enterics Project","University of Maryland, Baltimore, MD, USA","N/A","999","ISASimple_Gates_VIDA_case_control_RSRC","DS_0605f599e5","Gates Enterics Project","The Vaccine Impact on Diarrhea in Africa (VIDA) is a prospective, case control study to assess the causes and burden of diarrhea in children under five and determine the effectiveness of rotavirus vaccine at three sites in sub-Saharan Africa. Each site recruited moderate-to-severe diarrheal cases enrolled in three age strata from Sentinel Health Centres within the demographic surveillance system (DSS). One to three diarrhea-free controls were enrolled within two weeks of the case and were matched on age, gender, and residential area. Participants were assessed at enrollment and at a 60-day follow-up visit.","N/A"
"Public","PRISM ICEMR Cohort","Malaria","Female, Male","Infant, Child, Adult","Blood sample","Observational","Cohort","331","129","N/A","1,421","N/A","N/A","48,722","48,721","Uganda","2011, 2012, 2013, 2014, 2015, 2016, 2017","<a target='_blank' href='https://vectorbase.org/popbio-map/web/'>VectorBase</a>, <a target='_blank' href='https://plasmodb.org/plasmo/app/record/dataset/DS_4267c95a1c'>PlasmoDB</a>","Reproductive, maternal, newborn, child and adolescent health, Communicable disease","ICEMR","PRISM0001-1","Grant Dorsey","University of California, San Francisco, CA, USA","ClinEpiDB rel. 5, 2018-DEC-13","1","ISASimple_ICEMR_PRISM_cohort_RSRC","DS_0ad509829e","Grant Dorsey","The Program for Resistance, Immunology, Surveillance and Modeling of Malaria in Uganda (PRISM) was a longitudinal cohort study conducted in different transmission settings in Uganda. All children 6 months to 10 years old within a household and up to one primary caregiver were enrolled in a dynamic cohort, and children were excluded from follow-up after reaching 11 years of age. Participants had routine clinic visits roughly every 3 months and attended a study clinic any time they became ill.","N/A"
"Protected","South Asia ICEMR Surveillance","Malaria","Female, Male","Infant, Child, Adult","Blood sample","Observational","Cohort","1,546","77","1","1,546","100%","1","8,200","4,992","India","2012, 2013, 2014, 2015, 2016, 2017","N/A","Communicable disease","ICEMR","ICMERSOUTHASIA-1","Pradip K. Rathod","University of Washington, Seattle, WA, USA","ClinEpiDB rel. 8, 2019-JUL-02","8","ISASimple_ICEMR_South_Asia_surveillance_RSRC","DS_13c737a528","Pradip K. Rathod","A health center surveillance study of malaria was conducted in India. Febrile patients from 1-65 years old were recruited if they had a malaria-positive RDT or blood smear. Participants were followed every day of hospitalization.","N/A"
"Prerelease","PERCH Case Control","Respiratory condition","Female, Male","Infant, Child","Blood sample, Nasopharyngeal swab sample, Pleural fluid sample, Induced sputum sample, Endotracheal tube sample, Gastric fluid sample, Urine sample, Oropharyngeal swab sample","Observational","Case-control","9,557","877","N/A","9,557","N/A","N/A","20,605","9,557","Kenya, The Gambia, Mali, Zambia, South Africa, Thailand, Bangladesh","2011, 2012, 2013, 2014","N/A","Reproductive, maternal, newborn, child and adolescent health, Communicable disease","N/A","PERCH-1","Christine Prosperi","Johns Hopkins University, Baltimore, MD, USA","N/A","999","ISASimple_Gates_PERCH_case_control_RSRC","DS_1595200bb8","Christine Prosperi","The Pneumonia Etiology Research for Child Health (PERCH) study was a prospective, multi-center, case-control study of respiratory disease in children 1-59 months of age. Each site recruited cases with severe or very severe pneumonia from hospitals, randomly selected controls from the community, and age-frequency matched cases and controls. Participant observations were assessed at enrollment, and cases were followed up at 24 hours, 48 hours, and 30 days.","N/A"
"Public","India ICEMR Behavior Cross-sectional","Malaria","Female, Male","Infant, Child, Adult","Blood sample","Observational","Cross-sectional","233","111","N/A","497","N/A","N/A","N/A","497","India","2017","N/A","Communicable disease","ICEMR","INDIABCS1-1","Jane Carlton","New York University, New York City, NY, USA","ClinEpiDB rel. 21, 2022-MAR-03","14","ISASimple_ICEMR_India_behavior_cross-sectional_RSRC","DS_21205ebb16","Jane Carlton","A cross-sectional survey was conducted in Sundargarh, India to investigate the behavioral aspects of malaria risk. Participants of all ages were randomly identified from household censuses and were surveyed once.","N/A"
"Protected","GEMS1 HUAS/HUAS Lite Survey","Diarrheal disease","Female, Male","Neonate, Infant, Child","No samples","Observational","Cross-sectional","133,659","289","2","133,659","100%","2","N/A","N/A","The Gambia, Mali, Bangladesh, Kenya, India, Pakistan, Mozambique","2007, 2008, 2009, 2010, 2011","N/A","Reproductive, maternal, newborn, child and adolescent health, Communicable disease","GEMS","GEMSHUAS01-1","Gates Enterics Project","University of Maryland, Baltimore, MD, USA","ClinEpiDB rel. 7, 2019-APR-25","7","ISASimple_Gates_GEMS_gems1_case_control_huas_RSRC","DS_221d2bcac4","Gates Enterics Project","The Global Enteric Multicenter Study (GEMS) 1 HUAS/HUAS Lite surveys were three community-based Healthcare Services Utilization and Attitudes Surveys (HUAS, HUAS lite, and HUAS lite - Kenya) conducted in conjunction with the GEMS1 case control study. These cross-sectional surveys provide data on where parents seek care when their children have diarrheal disease, and their attitudes and practices concerning diarrhea, its prevention, and treatment.","N/A"
"Protected","Kalifabougou Malaria Cohort","Malaria","Female, Male","Infant, Child, Adult","Blood sample, Stool sample, Urine sample","Observational","Cohort","1,091","220","3","1,091","75%","4","74,843","59,173","Mali","2011, 2012, 2013, 2014, 2015, 2016, 2017, 2018","N/A","Communicable disease","N/A","KALIFA001-1","Peter D. Crompton","National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA","ClinEpiDB rel. 21, 2022-MAR-03","13","ISASimple_General_Crompton_cohort_RSRC","DS_22e3c3c070","Peter D. Crompton","A longitudinal cohort study of malaria was conducted in Kalifabougou, Mali. Healthy individuals 3-25 years were initally enrolled, with subsequent periodic enrollment of additional healthy volunteers. Participants had monthly or weekly scheduled visits and would come to the clinic for unscheduled visits when sick.","N/A"
"Protected","GEMS1A Case Control","Diarrheal disease","Female, Male","Infant, Child, Neonate","Stool sample","Observational","Case-control","14,242","579","10","14,242","100%","10","35,245","14,242","The Gambia, Mali, Bangladesh, Kenya, India, Pakistan, Mozambique","2011, 2012, 2013, 2014","N/A","Reproductive, maternal, newborn, child and adolescent health, Communicable disease","GEMS","GEMSCC1A03-1","Gates Enterics Project","University of Maryland, Baltimore, MD, USA","ClinEpiDB rel. 6, 2019-MAR-07","6","ISASimple_Gates_GEMS_gems1a_case_control_RSRC","DS_2a6ace17a1","Gates Enterics Project","The Global Enteric Multi-Center Study (GEMS) was a prospective, multi-center, case-control study of acute diarrhea in children 0-59 months of age. GEMS-1A is a one-year follow-on of GEMS looking at both moderate-to-severe diarrhea and less severe diarrhea cases. Each site recruited cases with diarrhea from hospitals or ambulatory facilities and up to three matched community controls per case. Participants were assessed at enrollment and at a 60-day follow-up visit.","N/A"
"Public","India ICEMR Severe <i>P. vivax</i> and <i>falciparum</i> Cohort","Malaria","Female, Male","Child, Adult","Blood sample","Observational","Cohort","51","193","N/A","51","N/A","N/A","209","209","India","2016, 2017","N/A","Communicable disease","ICEMR","ICESEVER1-1","Anupkumar R. Anvikar","National Institute of Malaria Research, New Delhi, India.","ClinEpiDB rel. 21, 2022-MAR-03","13","ISASimple_ICEMR_India_severemalaria_RSRC","DS_3b4a4e8f09","Anupkumar R. Anvikar","A hospital-based cohort study was conducted to compare severe malaria morbidity due to <i>Plasmodium falciparum</i> and <i>Plasmodium vivax</i>. Patients admitted to the hospital with severe malaria were enrolled and followed until discharge.","N/A"
"Controlled","Preventing Congenital Syphilis Cluster Randomized Trial","N/A","Female","Adult","Blood sample, Urine sample","Experimental","Randomized controlled/clinical trial","N/A","38","1","54,583","100%","1","N/A","54,583","Democratic Republic of the Congo, Zambia","2015, 2016, 2017","N/A","Reproductive, maternal, newborn, child and adolescent health, Communicable disease","N/A","GATESPCSRCT-1","Pierre Buekens","Tulane University, New Orleans, LA, USA","ClinEpiDB rel. 23, 2022-JUN-23","23","ISASimple_Gates_PCS_rct_RSRC","DS_40a4b145f4","Pierre Buekens","The Preventing Congenital Syphilis study was a cluster randomized trial conducted in Kinshasa and Lusaka at 26 antenatal care clinics. All women were eligble to enroll at their first visit. Data was collected at the first antenatal care visit, and women who tested positive for syphilis but were not treated were followed-up to ensure they received treatment before delivery.","N/A"
"Public","India ICEMR Meghalaya Cross-sectional","Malaria","Female, Male","Infant, Child, Adult","Blood sample","Observational","Cross-sectional","845","167","N/A","N/A","N/A","N/A","3,633","3,633","India","2018, 2019","N/A","Communicable disease","ICEMR","INDIAMEG1-1","Jane Carlton","New York University, New York City, NY, USA","ClinEpiDB rel. 21, 2022-MAR-03","18","ISASimple_ICEMR_India_meghalaya_cross-sectional_RSRC","DS_4670e06911","Jane Carlton","A cross-sectional survey was conducted in Meghalaya, India to assess the individual and village-level patterns of <i>Plasmodium</i> infection. Participants aged 1-69 were randomly identified from household censuses and were surveyed with resampling the following year.","N/A"
"Public","India ICEMR Fever Surveillance","Malaria","Female, Male","Adult, Child","Blood sample","Surveillance","N/A","N/A","129","N/A","954","N/A","N/A","962","962","India","2016, 2017","N/A","Communicable disease","ICEMR","INDIAFE01-1","Jane Carlton","New York University, New York City, NY, USA","ClinEpiDB rel. 7, 2019-APR-25","7","ISASimple_ICEMR_India_fever_surveillance_RSRC","DS_4902d9b7ec","Jane Carlton","A health center-based surveillance study was conducted to identify non-malarial causes of acute febrile illness. Patients from 1-70 years old who were febrile or reported a fever in the previous 48 hours and who had been triaged and found negative for malaria were enrolled. Participant observations were assessed at enrollment, and a few participants had 2 follow-up visits each.","N/A"
"Controlled","SCORE Niger <i>S. haematobium</i> Cluster Randomized Trial","Schistosomiasis","Female, Male","Child, Adult","Urine sample","Experimental","Randomized controlled/clinical trial","N/A","29","2","233,832","100%","2","N/A","233,832","Niger","2011, 2012, 2013, 2014, 2015","N/A","Communicable disease","SCORE","SCORENIGER-1","Dan Colley","University of Georgia, Athens, GA, USA","ClinEpiDB rel. 21, 2022-MAR-03","13","ISASimple_Gates_SCORE_niger_RSRC","DS_4d0fe88b6b","Dan Colley","To provide an evidence base for cost-effective schistosomiasis control, a five-year study cluster-randomised trial in Niger investigated six possible combinations of annual or biannual community-wide treatment, school-based treatment, and holidays from mass treatment over four years. The primary outcome of interest was prevalence and intensity of <i>Schistosoma haematobium</i> among 100 children aged 9-12 years sampled each year in each village. The relative reduction of prevalence was greater in biannual compared with annual treatment across all arms; however, the only significant difference was seen in areas with a high starting prevalence.","N/A"
"Controlled","Asia Pacific ICEMR Cambodian Cross-sectional","Malaria","Female, Male","Adult, Child","Blood sample","Observational","Cross-sectional","2,351","305","0","10,393","0","0","4,195","4,195","Cambodia","2017, 2018","N/A","Communicable disease","ICEMR","ASIAPAC-1","Ivo Mueller","Malaria: Parasites and Hosts Unit, Institut Pasteur, Paris, France ; Population Health and Immunity, Walter and Eliza Hall Institute, Melbourne, Australia ; University of Melbourne, Melbourne, Australia","ClinEpiDB rel. 25, 2022-NOV-09","25","ISASimple_ICEMR_sw_pacific_cs_RSRC","DS_4d72506014","Ivo Mueller","A cross-sectional study of malaria was conducted in Cambodia. Participants 2-80 years old living in selected households and who had been living in the study area for >3 months were surveyed.","N/A"
"Prerelease","LAKANA Cluster Randomized Trial","Diarrheal disease, Malaria, Respiratory condition","Female, Male","Infant","Blood sample, Stool sample, Urine sample, Nasopharyngeal swab sample","Experimental","Randomized controlled/clinical trial","N/A","N/A","N/A","N/A","N/A","N/A","N/A","N/A","Mali","N/A","N/A","Reproductive, maternal, newborn, child and adolescent health, Communicable disease","N/A","PREVIEW_Gates_REACH_LAKANA_rct","Per Ashorn","Tampere University, Tampere, Finland","N/A","999","ISASimple_Gates_REACH_LAKANA_rct_RSRC","DS_515a92c711","Per Ashorn","The <b>L</b>arge-scale <b>A</b>ssessment of the <b>K</b>ey health-promoting <b>A</b>ctivities of two <b>N</b>ew mass drug administration regimens with <b>A</b>zithromycin trial (LAKANA) has been designed to address the impact on mortality of quarterly and biannual azithromycin MDA when delivered to 1-11-month old infants in a high-mortality setting where malaria is holoendemic and there is a seasonal malaria chemoprevention (SMC) program in place.","N/A"
"Public","PRISM2 ICEMR Cohort","Malaria","Female, Male","Child, Adult, Infant","Blood sample","Observational","Cohort","80","233","N/A","531","N/A","N/A","36,565","36,565","Uganda","2017, 2018, 2019","<a target='_blank' href='https://vectorbase.org/popbio-map/web/'>VectorBase</a>","Communicable disease","ICEMR","PRISM0002-1","Grant Dorsey","University of California, San Francisco, CA, USA","ClinEpiDB rel. 21, 2022-MAR-03","13","ISASimple_ICEMR_PRISM2_cohort_RSRC","DS_51b40fe2e2","Grant Dorsey","The Program for Resistance, Immunology, Surveillance and Modeling of Malaria in Uganda 2 (PRISM2) is a longitudinal cohort study. Households were recruited for a dynamic cohort if they had at least 2 members under the age of 10, no more than 9 residents, and no plans to move in the next 2 years. Mosquito collections were performed every 2 weeks, routine clinic visits occurred every 4 weeks, and participants attended a study clinic any time they became ill.","N/A"
"Controlled","SCORE Burundi Mapping Cross-sectional","Schistosomiasis","Female, Male","Child","Stool sample, Urine sample","Observational","Cross-sectional","N/A","29","2","21,043","100%","2","N/A","21,043","Burundi","2014","N/A","Communicable disease","SCORE","SCOREBU01-1","Dan Colley","University of Georgia, Athens, GA, USA","ClinEpiDB rel. 21, 2022-MAR-03","13","ISASimple_Gates_SCORE_burundi_RSRC","DS_55fd455f5e","Dan Colley","The Schistosomiasis Consortium for Operational Research and Evaluation (SCORE) supported the mapping of <i>Schistosoma mansoni</i> prevalence in Burundi to determine the feasibility of moving toward elimination. A national survey of schoolchildren in Burundi used two detection methods- a single urine-circulating cathodic antigen rapid test and, in a subset of schools, duplicate Kato-Katz slide preparation from a single stool sample. The findings of this nationwide reassessment using the rapid test indicate that <i>Schistosoma</i> infection is still widespread in Burundi, although its average intensity is probably low.","N/A"
"Protected","MAL-ED 0-60m Cohort","Diarrheal disease, Respiratory condition","Female, Male","Neonate, Infant, Child","Blood sample, Stool sample, Urine sample","Observational","Cohort","2,145","893","43","2,145","83%","52","1,848,829","77,498","Bangladesh, Brazil, India, Nepal, Pakistan, Peru, South Africa, Tanzania","2009, 2010, 2011, 2012, 2013, 2014, 2015, 2016, 2017","<a target='_blank' href='http://microbiomedb.org/mbio/app/record/dataset/DS_9d44f0a9b5'>MAL-ED 2yr dataset on MicrobiomeDB</a>, <a target='_blank' href='http://microbiomedb.org/mbio/app/record/dataset/DS_71c725321c'>MAL-ED diarrheal dataset on MicrobiomeDB</a>","Reproductive, maternal, newborn, child and adolescent health, Communicable disease, Nutrition","N/A","MALED0003-1","David Spiro","Fogarty International Center, National Institutes of Health, Bethesda, MD, USA","ClinEpiDB rel. 21, 2022-MAR-03","12","ISASimple_Gates_MAL-ED_phase3_RSRC","DS_5c41b87221","David Spiro","The Etiology, Risk Factors, and Interactions of Enteric Infections and Malnutrition and the Consequences for Child Health Study (MAL-ED) was a multi-center longitudinal cohort study of enteropathogenic infection and undernutrition. Each site recruted 1 child per household within 17 days of birth and followed them for up to 60 months of age. More than one sample may have been collected on any given day of observation. A visual depiction of collection timpoints for various data types can be found below.","N/A"
"Prerelease","VIDA HUCS Gambia Mali Survey","Diarrheal disease","Female, Male","Neonate, Infant, Child","No samples","Observational","Cross-sectional","20,813","138","N/A","20,813","N/A","N/A","N/A","N/A","The Gambia, Mali","2015, 2016, 2017, 2018","N/A","Reproductive, maternal, newborn, child and adolescent health, Communicable disease","VIDA","VIDAGAMALI-1","Gates Enterics Project","University of Maryland, Baltimore, MD, USA","N/A","999","ISASimple_Gates_VIDA_HUCS_Gambia_Mali_survey_RSRC","DS_6741e4cc0a","Gates Enterics Project","During the course of the Vaccine Impact on Diarrhea in Africa (VIDA) study, a Health care Utilization and Coverage Survey (HUCS) was conducted semiannually as part of the Demographic Surveillance System (DSS) at each VIDA study site. In The Gambia and Mali, a random selection of children from three age strata was selected and the HUCS was conducted by the DSS team during their routine rounds. The goal of the survey was to assess rotavirus vaccine coverage and to determine where children in the DSS seek care for moderate-to-severe diarrhea.","N/A"
"Protected","ELICIT Randomized Controlled Trial","N/A","Female, Male","Neonate","Blood, Stool","Experimental","Randomized controlled/clinical trial","1,188","110","0","1,188","0","1","7,902","7,902","Tanzania","2017, 2018","N/A","Reproductive, maternal, newborn, child and adolescent health, Nutrition","N/A","ELICIT0001-1","Mark D. DeBoer","University of Virginia School of Medicine, Charlottesville, VA, USA","ClinEpiDB rel. 21, 2022-MAR-03","20","ISASimple_Gates_ELICIT_rct_RSRC","DS_6834a4c83b","Mark D. DeBoer","The Early Life Interventions for Childhood Growth and Development in Tanzania (ELICIT) study was a randomized controlled trial evaluating the efficacy of antimicrobials and nicotinamide in increasing growth. Infants aged 0-14 days old with no significant birth defects or neonatal illness were enrolled with their mothers and assigned to one of 4 intervention arms in a 2 x 2 factorial trial design. Participants were followed for 18 months.","N/A"
"Protected","GEMS1A HUAS Lite Survey","Diarrheal disease","Female, Male","Neonate, Infant, Child","No samples","Observational","Cross-sectional","62,193","66","1","62,193","100%","1","N/A","N/A","The Gambia, Mali, Bangladesh, Kenya, India, Mozambique, Pakistan","2011, 2012, 2013, 2014","N/A","Reproductive, maternal, newborn, child and adolescent health, Communicable disease","GEMS","GEMSCC0005-1","Gates Enterics Project","University of Maryland, Baltimore, MD, USA","ClinEpiDB rel. 7, 2019-APR-25","7","ISASimple_Gates_GEMS_gems1a_case_control_huas_RSRC","DS_6a93753102","Gates Enterics Project","The Global Enteric Multicenter Study (GEMS) 1A HUAS Lite surveys were 2 community-based Healthcare Services Utilization and Attitudes Surveys (HUAS Lite and HUAS Lite - Kenya) conducted in conjunction with the GEMS1A case control study. This cross-sectional survey provides data on where parents seek care when their children have diarrheal disease, and their attitudes and practices concerning diarrhea, its prevention, and treatment.","N/A"
"Controlled","SCORE Five Country CCA Evaluation Cross-sectional","Schistosomiasis","Female, Male","Child","Stool sample, Urine sample","Observational","Cross-sectional","N/A","10","3","4,305","100%","3","N/A","4,305","Cameroon, Cote dIvoire, Ethiopia, Kenya, and Uganda","2012","N/A","Communicable disease","SCORE","SCOREFC01-1","Dan Colley","University of Georgia, Athens, GA, USA","ClinEpiDB rel. 21, 2022-MAR-03","13","ISASimple_Gates_SCORE_five_country_RSRC","DS_6b79157ec1","Dan Colley","The Schistosomiasis Consortium for Operational Research and Evaluation (SCORE) supported the evaluation of a commercial point-of-care circulating cathodic antigen (POC-CCA) test for assessing <i>Schistosoma mansoni</i> infection prevalence in areas at risk in 5 countries- Cameroon, Côte d'Ivoire, Ethiopia, Kenya, and Uganda. The study concluded that one urine POC-CCA test can replace Kato-Katz testing for community-level <i>S. mansoni</i> prevalence mapping.","N/A"
"Controlled","SCORE Seasonal Transmission <i>S. haematobium</i> Cluster Randomized Trial","Schistosomiasis","Female, Male","Child, Adult","Stool sample, Urine sample","Experimental","Randomized controlled/clinical trial","N/A","22","1","58,753","100%","1","N/A","58,753","Cote dIvoire","2015, 2016, 2017, 2018, 2019","N/A","Communicable disease","SCORE","SCORESL01-1","Dan Colley","University of Georgia, Athens, GA, USA","ClinEpiDB rel. 21, 2022-MAR-03","11","ISASimple_Gates_SCORE_seasonal_RSRC","DS_6bd7dbd802","Dan Colley","In order to assess the impact of different control strategies against <i>Schistosoma haematobium</i> in seasonal transmission foci in Côte d'Ivoire, villages were randomly assigned to four intervention arms comparing annual mass drug administration (MDA) before (arm 1) or after (arm 2) the peak transmission, biannual treatment with praziquantel before and after the peak transmission season (arm 3), and annual MDA before the peak transmission season, coupled with focal chemical snail control using molluscicides (arm 4). The primary outcome was change in prevalence and intensity of <i>S. haematobium</i> infection in each of the three study population age groups over the study period. In the first year follow-up survey, a significant decrease of <i>S. haematobium</i> prevalence was observed in all study arms.","N/A"
"Controlled","LLINEUP Cluster Randomized Trial","Malaria","Female, Male","Neonate, Infant, Child, Adult","Blood sample","Experimental","Randomized controlled/clinical trial","20,792","164","8","115,542","89%","9","N/A","115,542","Uganda","2017, 2018, 2019","N/A","Communicable disease","N/A","LLINEUP01-1","Sarah Staedke","London School of Hygiene and Tropical Medicine, London, United Kingdom","ClinEpiDB rel. 21, 2022-MAR-03","14","ISASimple_Gates_LLINE-UP_rct_RSRC","DS_7c4cd6bba9","Sarah Staedke","The LLIN Evaluation in Uganda Project (LLINEUP), a pragmatic cluster-randomized trial embedded in the 2017-2018 long-lasting insecticidal net (LLIN) national distribution campaign, evaluated the effect of LLINs with and without piperonyl butoxide on malaria indicators in 104 health sub-districts (clusters) in Eastern and Western Uganda. Cross-sectional community surveys were conducted at baseline and at 6, 12, 18, and 25 months following LLIN distribution in ~50 randomly selected households per cluster; all children aged 2-10 years from enrolled households were assessed for malaria parasites, and a subset of 5-10 households per cluster were randomly selected for entomology surveys. To assess net integrity and chemical composition, 100 of each LLIN net type were withdrawn and replaced from selected households enrolled in the community surveys after 12 and 25 months.","N/A"
"Protected","GEMS1 Case Control","Diarrheal disease","Female, Male","Neonate, Infant, Child","Stool sample","Observational","Case-control","22,567","596","25","22,567","86%","29","60,958","22,567","The Gambia, Mali, Bangladesh, Kenya, India, Pakistan, Mozambique","2007, 2008, 2009, 2010, 2011","<a target='_blank' href='http://microbiomedb.org/mbio/app/record/dataset/DS_bb7b589593'>MicrobiomeDB</a>","Reproductive, maternal, newborn, child and adolescent health, Communicable disease","GEMS","GEMSCC0003-1","Gates Enterics Project","University of Maryland, Baltimore, MD, USA","ClinEpiDB rel. 5, 2018-DEC-13","5","ISASimple_Gates_GEMS_gems1_case_control_RSRC","DS_841a9f5259","Gates Enterics Project","The Global Enteric Multi-Center Study (GEMS) was a prospective, multi-center, case-control study of acute diarrhea in children 0-59 months of age. Each site recruited cases with severe diarrhea from hospitals or ambulatory facilities and up to three matched community controls per case. Participants were assessed at enrollment and at a 60-day follow-up visit.","N/A"
"Public","PROMOTE Birth Cohort 3 Randomized Controlled Trial","Malaria","Female, Male","Adult, Infant","Blood sample","Experimental","Randomized controlled/clinical trial","782","490","N/A","782","N/A","N/A","24,237","24,235","Uganda","2016, 2017, 2018","N/A","Reproductive, maternal, newborn, child and adolescent health, Communicable disease","PROMOTE","PROMO-1","Grant Dorsey","University of California, San Francisco, CA, USA","ClinEpiDB rel. 24, 2022-AUG-30","24","ISASimple_General_PROMOTE_BC3_cohort_RSRC","DS_8786631aaf","Grant Dorsey","A double-blind randomized controlled trial of monthly intermittent preventive treatment of malaria (IPTp) in HIV-uninfected pregnant women and infants with sulfadoxine-pyrimethamine (SP) vs dihydroartemisinin-piperaquine (DP). In cases where a woman had twins, find 2 records per woman, one for each infant, for visit post-partum visits.","N/A"
"Controlled","SCORE Rwanda Mapping Cross-sectional","Schistosomiasis","Female, Male","Child","Stool sample, Urine sample","Observational","Cross-sectional","N/A","30","2","19,934","100%","2","N/A","19,934","Rwanda","2014","N/A","Communicable disease","SCORE","SCORERW01-1","Dan Colley","University of Georgia, Athens, GA, USA","ClinEpiDB rel. 21, 2022-MAR-03","13","ISASimple_Gates_SCORE_rwanda_RSRC","DS_88b591c3e5","Dan Colley","The Schistosomiasis Consortium for Operational Research and Evaluation (SCORE) supported the mapping of <i>Schistosoma mansoni</i> prevalence in Rwanda to determine the feasibility of moving toward elimination. A national survey of Rwandan schoolchildren used two detection methods: the field standard Kato-Katz (KK) test to detect parasite eggs in stool and the more sensitive circulating cathodic antigen (CCA) rapid assay to detect schistosome antigen in urine. The results indicate that <i>S. mansoni</i> infection is still widespread in Rwanda and prevalence is much underestimated by KK testing.","N/A"
"Protected","Amazonia ICEMR Brazil Cohort","Malaria","Female, Male","Infant, Child, Adult","Blood sample","Observational","Cohort","252","248","0","640","0","1","3,186","3,186","Brazil","2010, 2011, 2012, 2014","N/A","Communicable disease","ICEMR","BRAZIL0001-1","Marcelo U. Ferreira","University of São Paulo, São Paulo, Brazil","ClinEpiDB rel. 21, 2022-MAR-03","13","ISASimple_ICEMR_Amazonia_Brazil_cohort_RSRC","DS_8e1f623542","Marcelo U. Ferreira","A longitudinal cohort study of malaria was conducted in the Brazilian Amazon. All residents >3 months of age were recruited to the open cohort with visits every 4-6 months. Household data was collected twice, but participants may have changed households at any study visit. Note that data subsets based on participant or sample variables will only include the first household a participant belonged to.","N/A"
"Public","India ICEMR Cross-sectional","Malaria","Female, Male","Child, Adult","Blood sample","Observational","Cross-sectional","1,393","172","N/A","3,267","N/A","N/A","3,442","3,442","India","2012, 2013, 2014","N/A","Communicable disease","ICEMR","INDIA0002-1","Jane Carlton","New York University, New York City, NY, USA","ClinEpiDB rel. 7, 2019-APR-25","7","ISASimple_ICEMR_India_cross_sectional_RSRC","DS_a5c969d5fa","Jane Carlton","A cross-sectional study of malaria in different transmission settings was conducted in India. Participants of all ages were randomly identified from household censuses that were conducted and surveyed once. Participants had follow-up visits if they were positive for <i>Plasmodium</i> at the first visit.","N/A"
"Protected","Amazonia ICEMR Peru Cohort","Malaria","Female, Male","Infant, Child, Adult","Blood sample","Observational","Cohort","487","144","2","2,447","40%","5","2,052,793","2,050,515","Peru","2012, 2013, 2014, 2015","N/A","Communicable disease","ICEMR","PERUL0002-1","Joseph M. Vinetz","Yale School of Medicine, New Haven, CT, USA","ClinEpiDB rel. 8, 2019-JUL-02","8","ISASimple_ICEMR_Amazonia_Peru_lon2_RSRC","DS_a885240fc4","Joseph M. Vinetz","A longitudinal cohort study of malaria was conducted at two sites in the Peruvian Amazon. Residents 3 years or older who planned to remain within the study area over the next two years were recruited. Participants were visited roughly every 3 months.","N/A"
"Prerelease","India ICEMR DAMaN Quasi-experimental Stepped-wedge","Malaria","Female, Male","Adult, Child","Blood sample","Experimental","Non-randomized","2,493","54","N/A","N/A","N/A","N/A","6,347","6,346","India","2019, 2020","N/A","Communicable disease","ICEMR","ICEMRINDIADAMAN-1","Jane Carlton","New York University, New York City, NY, USA","ClinEpiDB rel. 24, 2022-AUG-30","24","ISASimple_ICEMR_India_daman_non-randomized_RSRC","DS_be1995b20b","Jane Carlton","A cluster-assigned quasi-experimental stepped-wedge study with a pretest-posttest control group design was conducted in Odisha, India to evaluate if malaria camps reduce the prevalence of malaria compared to control villages which receive the usual malaria control interventions (e.g. IRS, ITNs), as detected by PCR.","N/A"
"Public","WASH Benefits Bangladesh Cluster Randomized Trial","Diarrheal disease","Female, Male","Neonate, Infant, Child","No samples","Experimental","Randomized controlled/clinical trial","11,517","141","N/A","11,549","N/A","N/A","25,035","N/A","Bangladesh","2012, 2013, 2014, 2015","N/A","Reproductive, maternal, newborn, child and adolescent health, Communicable disease, Nutrition","WASH Benefits","WASHBBANG-1","Andrew Mertens","University of California, Berkeley, CA, USA","ClinEpiDB rel. 21, 2022-MAR-03","16","ISASimple_Gates_WASHb_Bangladesh_rct_RSRC","DS_c56b76b581","Andrew Mertens","WASH Benefits Bangladesh was a cluster-randomized trial that assessed improvements in water quality, sanitation, handwashing (WASH interventions) and child nutrition on the primary outcomes of child growth and diarrhea. Geographically matched clusters (groups of household compounds) were randomized to one of six intervention arms (1. water quality, 2. sanitation, 3. handwashing, 4. nutrition, 5. combined water quality + sanitation + handwashing, and 6. combined water quality + sanitation + handwashing + nutrition) or control. Newborns from rural households in Bangladesh were enrolled, and outcomes were measured at 12 and 24 months after intervention delivery.","N/A"
"Controlled","SCORE <i>S. mansoni</i> Kenya and Tanzania Cohort","Schistosomiasis","Female, Male","Child","Stool sample","Observational","Cohort","20","14","3","1,582","100%","3","3,635","3,635","Kenya, Tanzania","2011, 2012, 2013, 2014, 2015","N/A","Communicable disease","SCORE","SCORESM01-1","Dan Colley","University of Georgia, Athens, GA, USA","ClinEpiDB rel. 21, 2022-MAR-03","13","ISASimple_Gates_SCORE_Sm_cohort_RSRC","DS_cb9893494e","Dan Colley","Multi-country, cluster-randomized trials compared the effectiveness of community-wide and school-based treatment regimens on prevalence and intensity of schistosomiasis. To assess the impact of two different treatment schedules on <i>S. mansoni</i>-associated morbidity in children, cohort studies were nested within the randomized trials conducted in villages in Kenya and Tanzania. These cohort studies used selected markers to monitor changes in a suite of schistosomiasis disease outcomes.","N/A"
"Controlled","SCORE Mozambique <i>S. haematobium</i> Cluster Randomized Trial","Schistosomiasis","Female, Male","Child, Adult","Urine sample","Experimental","Randomized controlled/clinical trial","N/A","23","3","81,632","100%","3","N/A","81,632","Mozambique","2011, 2012, 2013, 2014, 2015","N/A","Communicable disease","SCORE","SCOREMZ01-1","Dan Colley","University of Georgia, Athens, GA, USA","ClinEpiDB rel. 21, 2022-MAR-03","11","ISASimple_Gates_SCORE_moz_RSRC","DS_cc143c9cef","Dan Colley","The SCORE <i>S. haematobium</i> studies in Mozambique were community-level, cluster-randomized control trials designed to understand the impact of different schistosomiasis treatment strategies involving community-wide treatment, school-based treatment, and treatment holidays over a five-year period. Major outcomes were prevalence and intensity of schistosomiasis among 9 to 12 year old children, the highest risk group, at the end of the study. Four rounds of treatment, regardless of whether it was given in the community or school, resulted in a significantly greater reduction of <i>S. haematobium</i> prevalence than two rounds of treatment over a five-year period.","N/A"
"Controlled","SCORE <i>S. mansoni</i> Cluster Randomized Trial","Schistosomiasis","Female, Male","Child, Adult","Stool sample","Experimental","Randomized controlled/clinical trial","N/A","30","5","233,000","100%","5","N/A","233,000","Cote dIvoire, Kenya, Tanzania","2011, 2012, 2013, 2014, 2015, 2016","N/A","Communicable disease","SCORE","SCORECX01-1","Dan Colley","University of Georgia, Athens, GA, USA","ClinEpiDB rel. 21, 2022-MAR-03","10","ISASimple_Gates_SCORE_cx_RSRC","DS_d6a1141fbf","Dan Colley","The SCORE <i>S. mansoni</i> studies in Côte d'Ivoire, Kenya and Tanzania were community-level, cluster-randomized control trials designed to test optimal mass drug administration (MDA) regimens to control schistosomiasis. Villages with >10% <i>S. mansoni</i> prevalence were randomized to study arms that received a praziquantel MDA regimen that varied in the venue of MDA- either community-based or school-wide, and in the presence or absence of drug holidays during the four study years. Major outcomes were prevalence and intensity of schistosomiasis among 9 to 12 year old children, the highest risk group, at the end of the study.","N/A"
"Protected","Jilinde Prospective Cohort","HIV","Female, Male","Adult","No samples","Observational","Cohort","1,135","324","0","1,135","0","0","4,117","N/A","Kenya","2018, 2019, 2020, 2021","N/A","Communicable disease","Jilinde","GATESJILINRCT-1","Daniel Were","Jhpiego, Nairobi, Kenya","ClinEpiDB rel. 24, 2022-AUG-30","24","ISASimple_Gates_JILINDE_prospective_cohort_rct_RSRC","DS_d70aacce42","Daniel Were","The Jilinde (Bridge to Scale) project is implementing oral pre-exposure prophylaxis (PrEP) as a routine service for HIV prevention at a public health scale in Kenya. This prospective cohort study and accompanying qualitative data are part of the evaluation of the Bridge to Scale Program for Oral Pre-Exposure Prophylaxis Delivery among Key Populations, Adolescent Girls and Young Women (AGYW) in Kenya.","N/A"
"Controlled","SCORE Zanzibar <i>S. haematobium</i> Cluster Randomized Trial","Schistosomiasis","Female, Male","Child","Urine sample","Experimental","Randomized controlled/clinical trial","N/A","13","1","81,476","100%","1","N/A","72,612","Zanzibar","2012, 2013, 2014, 2015, 2016, 2017","N/A","Communicable disease","SCORE","SCOREZAN1-1","Dan Colley","University of Georgia, Athens, GA, USA","ClinEpiDB rel. 9, 2019-SEP-05","9","ISASimple_Gates_SCORE_zanzibar_RSRC","DS_eddb4757ba","Dan Colley","The Zanzibar Elimination of Schistosomiasis Transmission (ZEST) project aimed to assess biannual mass drug administration (MDA) applied alone or with complementary snail control or behavior change interventions for the reduction of <i>Schistosoma haematobium</i> prevalence and infection intensity in children from Zanzibar and to compare the effect between the clusters. Major outcomes were prevalence and intensity of schistosomiasis among 9 to 12 year old children, the highest risk group, at the end of the study. The study found that prevalence was significantly reduced in all study arms, but transmission was not interrupted.","N/A"
"Controlled","Myanmar ICEMR Malaria Cohort","Malaria","Female, Male","Child, Adult","Blood sample","Observational","Cohort","2,700","130","0","2,700","0","0","5,851","5,851","Myanmar","2018, 2019","N/A","Communicable disease","ICEMR","MYANMAR-1","Christopher V. Plowe","Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, USA","ClinEpiDB rel. 25, 2022-NOV-09","25","ISASimple_ICEMR_Myanmar_cohort_RSRC","DS_f3ce0be2f1","Christopher V. Plowe","A longitudinal cohort study of malaria was conducted in Myanmar. Participants >6 months of age were recruited and followed every 2-4 weeks for up to 4 weeks for uninfected individuals and up to 12 weeks for infected individuals. Dried blood spot samples were collected and analyzed by ultra sensitive PCR.","N/A"
"Private","Namibia rfMDA RAVC Cluster Randomized Trial","N/A","N/A","N/A","N/A","N/A","N/A","4,499","247","0","17,461","0","0","N/A","9,845","N/A","N/A","N/A","N/A","N/A","GATESNAMIBRCT-1","Michelle Hsiang","University of Texas Southwestern Medical Center, Dallas, TX, USA; University of California, San Francisco, CA, USA","N/A","999","ISASimple_Gates_Namibia_RACD_rfMDA_RAVC_rct_RSRC","DS_f559aee789","Michelle Hsiang","A cluster-randomized control trial of reactive focal mass drug administration (rfMDA) and reactive focal vector control (RAVC) to reduce malaria transmission was performed in Namibia. Individuals residing within 500 meters of an index case were recruited. Participant observations were assessed at enrollment and at the endline cross-sectional survey, and data on the cumulative incidence of locally acquired malaria cases (the primary outcome) were extracted from health care facility rapid reports.","N/A"
"Prerelease","VIDA HUCS Kenya Survey","Diarrheal disease","Female, Male","Neonate, Infant, Child","No samples","Observational","Cohort","56,087","87","N/A","56,087","N/A","N/A","177,013","N/A","Kenya","2015, 2016, 2017, 2018","N/A","Reproductive, maternal, newborn, child and adolescent health, Communicable disease","VIDA","VIDAHUCSKENYA-1","Gates Enterics Project","University of Maryland, Baltimore, MD, USA","N/A","999","ISASimple_Gates_VIDA_HUCS_Kenya_survey_RSRC","DS_f89ed22806","Gates Enterics Project","During the course of the Vaccine Impact on Diarrhea in Africa (VIDA) study, a Health care Utilization and Coverage Survey (HUCS) was conducted semiannually as part of the Demographic Surveillance System (DSS) at each VIDA study site. In Kenya, the HUCS questions were administered to the primary caretakers of all age-eligible children during each DSS round. The goal of the survey was to assess rotavirus vaccine coverage and to determine where children in the DSS seek care for moderate-to-severe diarrhea.","N/A"
"Protected","PROVIDE Randomized Controlled Trial","Diarrheal disease","Female, Male","Neonate, Infant, Child","Stool sample, Urine sample, Blood sample, Maternal blood sample, Maternal breast milk sample, Saliva sample, Breath sample","Experimental","Randomized controlled/clinical trial","700","742","4","700","67%","6","467,539","27,907","Bangladesh","2011, 2012, 2013, 2014","N/A","Reproductive, maternal, newborn, child and adolescent health, Communicable disease","N/A","PROVIDE01-1","William A. Petri","University of Virginia, Charlottesville, VA, USA","ClinEpiDB rel. 21, 2022-MAR-03","13","ISASimple_Gates_PROVIDE_rct_RSRC","DS_fe95d702c3","William A. Petri","The Performance of Rotavirus and Oral Polio Vaccines in Developing Countries (PROVIDE) study was a randomized controlled trial evaluating oral vaccine efficacy in Bangladesh. Infants aged 0-7 days old with no congenital abnormalities or birth defects and no abnormal stools since birth were enrolled with their mothers and assiged to one of 4 intervention arms in a 2 x 2 factorial trial design. Participants were followed for two years. A visual depiction of collection timpoints for various data types can be found below.","N/A"
